Who will benefit?
New and aspiring marketers and those wanting to refresh their marketing thinking and be fitter to handle today’s healthcare environment.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh